Aarti Drugs Valuation

Q: What is the Fair Price of AARTIDRUGS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

AARTIDRUGS (₹520.75) is trading above our estimate of [[fair value]] (₹376.67)

Is AARTIDRUGS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AARTIDRUGS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AARTIDRUGS (₹520.75) is trading above our estimate of fair value (₹376.67)

Significantly Below Fair Value: AARTIDRUGS is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AARTIDRUGS?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for AARTIDRUGS. This is calculated by dividing AARTIDRUGS's market cap by their current preferred multiple.
What is AARTIDRUGS's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	₹47.91b

AARTIDRUGS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.2x
Enterprise Value/EBITDA	17.7x
PEG Ratio	0.8x

Price to Earnings Ratio vs Peers

How does AARTIDRUGS's PE Ratio compare to its peers?

The above table shows the PE ratio for AARTIDRUGS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	46.9x
500288 Morepen Laboratories	40.8x	n/a	₹48.1b
SUPRIYA Supriya Lifescience	34.9x	17.2%	₹47.2b
524735 Hikal	67.5x	45.8%	₹45.8b
509079 Gufic Biosciences	44.3x	n/a	₹38.3b
AARTIDRUGS Aarti Drugs	30.6x	36.4%	₹47.9b

Price-To-Earnings vs Peers: AARTIDRUGS is good value based on its Price-To-Earnings Ratio (30.6x) compared to the peer average (46.9x).

Price to Earnings Ratio vs Industry

How does AARTIDRUGS's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.1%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: AARTIDRUGS is good value based on its Price-To-Earnings Ratio (30.6x) compared to the Indian Pharmaceuticals industry average (41.6x).

Price to Earnings Ratio vs Fair Ratio

What is AARTIDRUGS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AARTIDRUGS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	30.6x
Fair PE Ratio	43.5x

Price-To-Earnings vs Fair Ratio: AARTIDRUGS is good value based on its Price-To-Earnings Ratio (30.6x) compared to the estimated Fair Price-To-Earnings Ratio (43.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.